Posted on Authorea 10 Jul 2021 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.162588392.26373522/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. etdb h mrec fti e netosdsaei ae21 eutdi rgadvciedevelopment vaccine and drug in resulted 2019 late pre- in ‘ challenge disease enormous at infectious The performed new robust years. rapidly this of being in of couple emergence last assessed the the be for by healthcare sented to dominated clinical practice. has needs are clinical pandemic on novel effectiveness COVID-19 trials in potential effect The their used such – are but its Until pandemic they appealing, COVID demonstrate providers. before the theoretically to trials healthcare from be clinical to lessons performed may the important be options learn and should to therapeutic patients community trials our toxicology to the clinical performed, important (acetaminophen) robust paracetamol are following need that injury we outcomes liver preventing However, for treatment overdose. new promising a is Fomepizole Abstract 9216 242 0131 (+44) 4TJ EH16 Edinburgh Crescent France Little [email protected] 47 Institute Research Medical Queen’s The Edinburgh of University Science Cardiovascular for Centre University/BHF 4TJ EH16 Edinburgh, Edinburgh, Crescent, France author: of Little University Corresponding 47 Science, Institute, Cardiovascular Research Medical for Queen’s Centre Toxicology, The and Therapeutics Pharmacology, Author: Keywords: Title: Running be to practice. Title: needs clinical effectiveness in their used but are patients appealing, from they our lessons theoretically before to the be trials important learn may clinical are should options community that robust therapeutic toxicology outcomes in novel the clinical assessed potential performed, on are – effect trials pandemic its such COVID Until demonstrate the to providers. However, healthcare performed overdose. to be (acetaminophen) important to paracetamol and trials following injury clinical liver robust preventing need for we treatment new promising a is Fomepizole Abstract 2021 10, July 1 Dear James paracetamol in liberally more overdose used be should Fomepizole CON: dnug University Edinburgh h esn fCVDsol ud u s ffmpzl nprctmloverdose paracetamol in fomepizole of use our guide should COVID of lessons The ae Dear W James aaeao,aeaiohn vroe fomepizole overdose, acetaminophen, Paracetamol, 1 oeioeDbt Con Debate Fomepizole 1 . rfso ae .Dear W. James Professor apspeed’ warp hnCVDwsfis dnie,ciiin erhdfrlicenced for searched clinicians identified, first was COVID When . 1 Posted on Authorea 10 Jul 2021 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.162588392.26373522/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. e xesv ramn,tetxclg omnt hudfcso enn h pia oeo NAC. of dose optimal the defining on treatment advocating NAC focus Before dose should the toxicity. community high to dose-limiting toxicology of producing compared the the not trials regimens treatment, reactions of clinical from new expensive expectation drug 2 are clear new reasonable adverse phase There a a is allow of with injury. It regimes patients patients liver rates selected new prevent lower that in weight. These to substantially liver [16] regimen.[17] NAC body produce prevent enough 21-hour 15] their that receiving standard to fomepizole. on studies[14, NAC be using alone only observational not administering than sufficient may based and cheaper for overdose is be substantially 13] large not be that will a to modelling[12, do to NAC taking overdoses alternatives likely we mathematical of larger cheaper is importantly, pharmacology, dose approach for be most basic a This NAC may perhaps receive patients. there of patients and of therapy, Currently, dose Finally, group new this higher a in fomepizole. a effectiveness.[11] injury for using using clinical target by demonstrate whether correct to presented know failed the option circulation. and enzyme is the past P450 expensive in However, the inhibition the paracetamol use in sense. enzyme of indication its theoretical concentration P450 makes this of high this in If Advocates a enzymes tested of is practice. P450 been effectiveness there the have clinical clinical when inhibit inhibitors routine the overdoses to in large for ability overdose in evidence fomepizole’s paracetamol role trial Given treat a randomised has to disease. robust, it heart used on ischaemic suggest mouse insist is in in to it performed works reasons before be it of fomepizole cannot number because trials a medicine as clinical are a saying frequency There prescribing by same cardiologists the position – imagine that that overdose defending to suggested paracetamol and hard is a models is following it hospital It Sometimes that to infarction. performed. presents evidence myocardial someone be trial minutes to 5 that no need every confirm is trials UK, studies These there clinical largely However, man. performed impressive, in paracetamol.[10] well ‘ is injury humans, of liver fomepizole In metabolism prevents inhibition 9] for oxidative fomepizole the group.[8, base the Jaeschke’s through evidence Hartmut inhibits mainly pre-clinical of fomepizole paracetamol work The of the activation. to phase mice, kinase due metabolism in Furthermore, N-terminal the is that injury. c-Jun overdose enzymes after liver P450 for of paracetamol injury cytochrome responsible for liver the is of that prevents treatment inhibitor (NAPQI) fomepizole a potent metabolite a toxic as is paracetamol Fomepizole a potential ability the action. its as produce The to of emerged dehydrogenase.[7] mechanism due this poisoning has alcohol to alcohol toxic fomepizole enzyme unrelated for space, the treatment effective this inhibit an as Within to treatment toxicologists to new known group. well effective is risk Fomepizole need high we this overdose in paracetamol candidate. new injury significant potential liver patients a For overdose.[6] prevent following after to late hours 20 delayed. strategies 100% hospital around is near than to treatment greater is when present delayed NAC substantially is who acetylcysteine then treatment drops overdose, when effectiveness is ineffective the Cur- its near overdose of However, is paracetamol treatments. NAC hours failure. 8 after new liver within preventing for injury at commenced liver need effective is preventing unmet treatment for clear If NAC). treatment a (n-acetylcysteine, effective is There only the common. rently, to is treatment. be together overdose untested come may (acetaminophen) an and Fomepizole pre- Paracetamol prescribing COVID study. doctors of before large lessons in trials the robust randomised resulted learn a robust we that in perform unless hope tested meta-analysis hydroxychloroquine community’s a when initial toxicology subsequent ineffective the the fact, proved In Despite it care.[4] patients.[5] hydroxychloroquine, standard harm scribing received treated who may were endpoint. patients COVID hydroxychloroquine primary 3155 with to suggests the patients compared hospitalised as drug 1561 mortality this when measured with benefit no that using had trial evidence hydroxychloroquine the promoted limited clinical demonstrated pandemic, this who randomised the on leaders of large based profile it start a prescribed the high doctors from were Fortunately, and COVID,[3] There base. treat benefit.[2] and prevent possible to Hydroxychloroquine hydroxychloroquine a treatment. has suggested effective it studies because potentially treatment observational a potential with a as consistent identified action was of mechanisms w rascno epromdi lncltoxicology’. clinical in performed be cannot trials sprctmloeds scmo hsi nre nthe In untrue. is this common is overdose paracetamol As nvitro in 2 Recovery ciiyaantSR-o-[]aderysmall early and SARS-CoV-2[1] against activity ltomtiltse utpetetet in treatments multiple tested trial platform Recovery conclusively Posted on Authorea 10 Jul 2021 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.162588392.26373522/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. rma nentoa olbrtv eaaayi frnoie ras a omn22;1:2349. SN, 12: Goodman 2021; Commun D, COVID-19 Nat Webb Moher in trials. SR, W, chloroquine randomized Walsh Zhong and of RJ, hydroxychloroquine FG, meta-analysis Ulrich with Zampieri collaborative NA, international outcomes R, Turner an Mortality M, Wrenn from TY, Shahzad LG. HL, TB, Tseng Hemkens Wong Seto JPA, AB, M, VS, Troxel Ioannidis Velinova Sampaio Rivera-Martinez I, H, JM, A, A, Rosjo Thirion-Romero Weehuizen Nichol Meza-Meneses Remigio-Luna R, JE, SA, S, L, BJ, Rosa Narayanasamy Stout McVerry Perrin R, S, S, Rolfe R, C, Naggie Perez-Padilla S, McArthur Soliman S, L, Rodriguez-Llamazares MN, Perez Murthy FW, Lyngbakken NL, Rockhold MJ, Kreuels TH, Okeke NE, Mulligan PG, Lin SM, Kremsner A, WP, O’Brien KS, Mourad Lin LA, Khan SC, Novack F, YC, J, CM, Morpeth Jurado-Camacho Lin Hernandez-Cardenas WM, Akram R, AC, T, Monteiro Jin Gordon BS, P, Le B, A, Berrevoets Almeida Abella Elfakir CY, Igau de V, T, YW, Kuo O, EF, Dubee Huang Benfield Dalgard B, L, Abdo LN, AIM, L, Cowan Derde Hoepelman Belkhir S, YZ, GC, AW, T, Cohen Melo Abd-Elsalam WS, Hills Baker de Chung MVG, LR, J, CY, Lacerda Cheng Baden Hooft de SH, S, EVFF, Cheng Van’t TC, Azhar P, Chen YM, CP, Janiaud Chen NJ, Arabi MAH, DC, AM, White Angus JA, Schmitt Covid-19. Watson RK, C, Amaravadi with J, Patients Axfors Tarning Hospitalized K, 2030-40. in Rowan 5. 383: Hydroxychloroquine Chappell A, 2020; of JK, Montgomery Med Effect Baillie WS, J J, MJ. A, Engl Lim Ustianowski Landray Underwood N M, K, J, R, Wiselka Faccenda Haynes Jeffery JR, J, E, T, Emberson Williams N, Juszczak Jaki T, Staplin Felton SN, JL, T, Faust Bell Whitehouse LC, L, B, Linsell Subse- e20044. Prudon M, and E, Mafham 22: Treatments P, Elmahi 2020; COVID-19 Horby Unproven Res RC, Internet Group of Med Promotion 4. J Trump’s Study. of Observational Impact Trends: O. Internet Niburski quent 105949. K, D. Raoult 56: Niburski P, and 2020; non-randomized Brouqui 3. Agents open-label Remdesivir JM, V, Antimicrob an Rolain Giordanengo G. of B, J J, results Scola Int Xiao Courjon La COVID-19: B, trial. W, E, of Doudier treatment clinical Chabriere Zhong M, P, a Mailhe Colson as Z, azithromycin L, S, and Hu Meddeb Honore Hydroxychloroquine H, VT, Z, Dupont Hoang P, Tissot Shi Parola VE, 2020; M, JC, Vieira Res Lagier Xu Cell P, Gautret J, vitro. 2. in Liu (2019-nCoV) X, coronavirus Yang novel L, emerged 269-71. recently Zhang 30: the R, inhibit Cao effectively chloroquine M, paracetamol Wang in calmangafodipir 1. of Trial POP the on References: Investigator Chief a the without was treatments a JWD overdose. NAC prescribing as patients. start interest: dose advocated our COVID, to of high for in is Conflict hydroxychloroquine include benefit option the like of treatments easier follow becomes evidence Candidate the fomepizole to robust do, is community without to danger trials. treatment toxicology The thing 2 the hard base. phase for the evidence from robust is time efficacy This and the clinical failure fomepizole. is liver of and Now and evidence stay have dataset. of safety that length randomised adequate to hospital from the injury, data an data of have liver have example robust not as not have do such we do not outcomes But we do important overdose. We clinically paracetamol for about treatment. treatment trials a stop fomepizole-induced as NAC, to safety. promise A with has about decisions Fomepizole treatment questions injury. informs prolonged these which liver unnecessary to having biomarker significant answers patients key the of in know the cases result is may increased ALT benign, paracetamol into 15 if as of of translate even dose 6 ALT, hepatotoxic could in in caution. potentially activity of rise increase (ALT) a degree not transaminase ALT a with do alanine for small We combined in reasons increase when this poisoning. are unlikely, small there alcohol a Although and toxic demonstrated paracetamol safety subjects.[18] of fomepizole on excellent healthy treatment of overdosed an have – trial have who 1 indication patients phase to licenced in A claimed its safe in is is correct it it if be as know to defended seems occasionally This is overdose profile. paracetamol in use Fomepizole eoeyTrial Recovery n oetgte opromlrepafr rast vlaenwtreatments new evaluate to trials platform large perform to together come and 3 Posted on Authorea 10 Jul 2021 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.162588392.26373522/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. 8 aosnD eata S arnS,Crir W catnK.Eet f4-methylpyrazole, of Effects KE. McMartin 455-61. EW, 8: 1990; Carriere Med SK, Emerg J Barron humans. CS, healthy in Sebastian antidote, D, glycol methanol/ethylene Jacobsen trial. controlled randomised 18. Cooper a adverse J, of poisoning: Coyle 697-704. Reduction A. paracetamol EA, 383: Gray for Sandilands DJ, 2014; Webb treatment M, Lancet A, Veiraiah acetylcysteine Eddleston AD, intravenous SH, Vliegenthart from SC, Thomas Lewis effects HK, I, Butcher Thanacoody A, JW, Rodriguez Clin overdose:JG, Dear (ATOM-2). paracetamol DN, dose Massive Bateman acetylcysteine NA. increased 17. Buckley and 1055-65. BSH, charcoal from activated Chan 55: Outcomes of CB, 2017; SL. effect Page (Phila) 1263-72. the Toxicol Greene KA, of 83: DM, Kirby study 2017; GK, Wood observational Pharmacol Isbister an AM, Clin AL, Dines J Chiew Br CL, study. Davies 16. observational JRH, retrospective Archer a PI, overdose: prompt paracetamol Dargan despite massive 405-10. DJB, injury 54: paracetamol Marks liver 2016; Plasma with (Phila) JW. 15. Toxicol relationship Dear Clin dose-dependent DN, acetylcysteine. Bateman a intravenous M, has with Eddleston treatment presentation K, acetaminophen hospital Al-Hourani massive at HK, after concentration Beckwith N-acetylcysteine DG, of Cairney dose 14. 1-6. appropriate and 2019: most present (Phila) the past, Toxicol is Clin duration: What overdose? RG. and Hendrickson dose 91-8. acetylcysteine 13. 50: and 2012; Acetaminophen (Phila) Toxicol DN. Clin Bateman 1284-96. future. paracetamol BH, 58: severe Rumack 2020; for (Phila) treatments Toxicol 12. mitochondrial Clin and review. Metabolic SC. systematic WE. Med Curry Freeman a J RD, LH, poisoning: Yeager Volunteers. Gerkin ME, Human BH, Mullins in Rumack 11. Acetaminophen H, of Jaeschke 169-76. Metabolism JY, Oxidative 16: Akakpo on 2020; ES, Toxicol 4-Methylpyrazole Fisher of A, Effect Padilla-Jones The AM, Kang Toxicol Exp 10. Hum 4-Methylpyrazole hepatocytes. H. human Jaeschke 1310-22. primary BH, in Rumack 37: and SC, 2018; mice Kumer 57-68. in HM, hepatotoxicity Ni 170: acetaminophen SE, against 2019; Kandel protects A, Sci Ramachandran Toxicol JY, Kinase. Akakpo n-Terminal Rumack 9. c-Jun WX, 2216-23. of Ding Inhibition BD, Hepatotoxicity 360: Freudenthal Acetaminophen by 2009; MW, Against Mice Jaeschke Med Protects 4-Methylpyrazole in MA, J With Schaich Treatment Engl Delayed L, N H. Duan Jaeschke 1988; A, BH, poisoning. Ramachandran Med methanol JY, J and Akakpo glycol Engl 8. ethylene N for Fomepizole 1985). of J. treatment to Brent the (1976 7. in study N-acetylcysteine multicenter oral national of Efficacy the 1557-62. BH. of 319: Rumack Analysis KW, Kulig overdose. GL, acetaminophen Knapp MJ, Smilkstein 6. 4